使用β-阻断剂预防突然死亡. 审查可能的贡献性行动
Circulation
|December 1, 1991
概括
β抑制剂是唯一已被证明可以降低高血压和心肌梗塞后患者突然死亡风险的治疗方法. 它们的抗动作用,与其他机制一起,有助于这种显著的好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 高血压研究 高血压研究
背景情况:
- 高血压是冠状动脉疾病 (CAD) 的一个主要风险因素.
- 突发死亡是高血压和心肌梗塞后心脏病发作 (MI) 患者的主要死亡原因.
- 有效的治疗策略必须侧重于降低心脏突然死亡的风险.
研究的目的:
- 审查β-阻断剂的各种作用.
- 讨论这些影响如何有助于降低突然死亡风险.
- 为了比较β抑制剂与其他药理干预措施的疗效.
主要方法:
- 临床研究和动物实验数据对β-上腺素受体对抗剂的审查.
- 对经过测试的药理干预措施来降低突然死亡风险的分析.
- 讨论β阻塞的抗和其它潜在机制.
主要成果:
- 贝塔腺素受体对抗剂是唯一有效降低突然死亡风险的药理学药物.
- 贝塔阻塞显示出抗动作用,特别适用于心室动引起的突然心脏死亡.
- 贝塔抑制剂的有益作用很可能是由于多种作用的总和,而不仅仅是抗胰岛症或抗失律作用.
结论:
- 贝塔抑制剂治疗对于管理高血压和降低后心脏病发作患者的死亡率至关重要.
- 贝塔抑制剂的多方面作用,包括抗作用,是预防心脏突然死亡的关键.
- 有限作用机制的药物没有实现类似的突然死亡风险降低.
相关概念视频
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Prevention of Further Absorption of Poison
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...


